{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:46:32Z","timestamp":1777927592609,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>A 19 year old man was diagnosed newly acquired HIV and prescribed bictegravir\/emtricitabine\/tenofovir alafenamide at his initial visit for HIV care. The genotype results from that initial visit returned two\u00a0weeks later, showing high-level multi-class transmitted drug resistance, including multiple resistance-associated mutations (RAM) in the integrase gene. Although he had an initial substantial decline in viremia in the first 4\u00a0weeks, it was felt that the risk of subsequent failure was too high, and his antiretroviral treatment (ART) regimen was therefore changed to daily dolutegravir and darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide, plus injected lenacapavir. He had durable virologic suppression on this new regimen for 12\u00a0months as of his last follow-up. This case of high-level multi-class transmitted drug resistance, in the context of rapid emergence of resistance to dolutegravir where it has been used as part of a salvage regimen, suggests that assessing for RAM in the integrase gene should be added to the currently recommended resistance testing for all patients with newly acquired HIV prior to initiating ART.<\/jats:p>","DOI":"10.1177\/09564624251396374","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:36:15Z","timestamp":1762774575000},"page":"319-322","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-8176","authenticated-orcid":false,"given":"Theodore R.","family":"Miller","sequence":"first","affiliation":[{"name":"Apicha Health Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gruta","sequence":"additional","affiliation":[{"name":"UCSF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymund","family":"Sison","sequence":"additional","affiliation":[{"name":"Apicha Health Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Fierer","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"1","key":"e_1_3_5_2_2","first-page":"230290","article-title":"Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV outpatient study: 1999\u20132008","volume":"2012","author":"Buchacz K","year":"2012","unstructured":"Buchacz K, Baker R, Ward DJ, et al. Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV outpatient study: 1999\u20132008. AIDS Res Treat 2012; 2012(1): 230290.","journal-title":"AIDS Res Treat"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/13596535231201162"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.08.031"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0100"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15122426"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11010221"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz372"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy463"},{"key":"e_1_3_5_10_2","volume-title":"Guidance for HIV-1 genotype resistance testing","author":"NYC Department of Health and Mental Hygiene","year":"2025","unstructured":"NYC Department of Health and Mental Hygiene. Guidance for HIV-1 genotype resistance testing. NYC Department of Health and Mental Hygiene, 2025. https:\/\/www.nyc.gov\/assets\/doh\/downloads\/pdf\/csi\/iart-guidance-genotype-resistance-testing.pdf (Accessed 9 October 2025)."},{"key":"e_1_3_5_11_2","unstructured":"UCSF National Clinician Consultation Center (NCCC). Consultation occurred December 8 2023 UCSF national clinician consultation center. https:\/\/nccc.ucsf.edu\/"},{"key":"e_1_3_5_12_2","unstructured":"Stanford University. INSTI resistance notes - HIV drug resistance database 2024. https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/INSTI\/#55Rhee2022 (Accessed 4 September 2024)."},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"e_1_3_5_15_2","unstructured":"DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2022. Published online. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab583"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-017-2764-9"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002394"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw382"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00553-9"},{"key":"e_1_3_5_21_2","unstructured":"European AIDS Clinical Society (EACS). EACS guidelines 2023. https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf (Accessed June 2024)."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13204"},{"key":"e_1_3_5_23_2","unstructured":"Diagnostics Q. HIV-1 genotype. 2024. Accessed April 16 2025."}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251396374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624251396374","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251396374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:47:19Z","timestamp":1777675639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624251396374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/09564624251396374"],"URL":"https:\/\/doi.org\/10.1177\/09564624251396374","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}